INO

Inovio Pharmaceuticals Inc. (INO) | Rumor.io

Inovio Pharmaceuticals

INO

Attention (50-day avg)0%

Attention rank (50-day avg)#760

Bullish sentiment (50-day avg)88%

Price to earnings ratio-0.65

Market capitalization121M

Earnings per share-1.03

Dividend yield (TTM)—

Revenue (annual)65.3K

Net income (annual)-84.9M

Social

What share of all stock conversation is about INO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% 0	0% -0.01

Sep 29

Fosun Pharma has acquired exclusive rights to market VGX-3100 in China and Greater China for ~ $108M.
VGX-3100 has been successful in clinical trials, with experts praising its potential.
The company is awaiting FDA label negotiations, with some investors expecting a price increase once negotiations are confirmed.

Generated by AI

Sentiment

Of the messages about INO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	80% +13.33	68.66% -13.89	82.57% -8.7	88.54% +2.83
Bearish	20% -13.33	31.34% +13.89	17.43% +8.7	11.46% -2.83

Bullish· Sep 3

Institutional buying is evident, with huge candles forming in the stock's chart.
The FDA's acceptance of Inovio's BLA application historically leads to a high approval rate, with around 70-80% of accepted applications being approved in the first review cycle.
The stock's upward momentum is poised to continue, with the potential for a 100% increase in price over the coming weeks, given its current valuation and upcoming binary event.

Bearish· May 21

The company's warrant overhang is a significant burden, with warrant holders potentially shorting the stock, leading to a potential collapse.
The recent news about the company's product is a "nothing burger" and confirms the desperate state the company is in, with a long and uncertain timeline for final approval.
The stock's lack of movement despite significant news, including a potential cure for all types of cancer, is due to the company's management and the stock's dilution, making it unlikely to make a meaningful move.

Generated by AI

Topics

Of the messages about INO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	94.74%	76.06%	77.01%
Technical Analysis	0%	0%	9.86%	17.13%
Controversies	0%	5.26%	9.86%	3.07%
Macro	0%	0%	4.23%	0.31%
Earnings	0%	0%	0%	0.69%
Analysts	0%	0%	0%	1.79%

Earnings· Mar 1

Inovio Pharmaceuticals reported a loss of $0.50 per share, missing the consensus estimate of a loss of $0.33 per share.
The company's revenue of $1.77 million beat the consensus estimate of $1.46 million.
Inovio's net loss widened significantly in the fourth quarter, with a net loss of $106.9 million, a 340% increase from the prior-year period.

Analysts· Feb 12

Oppenheimer analyst Hartaj Singh initiated coverage on Inovio Pharmaceuticals with an Outperform rating and a $35 price target, citing the company's differentiated COVID-19 vaccine and overall DNA platform.
Singh believes Inovio's COVID-19 vaccine has a better safety and tolerability profile, which could generate higher uptake in a low-risk population, and that the company's overall DNA platform "should not be overlooked".
Inovio Pharmaceuticals shares are trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and announced a $35 price target, with the stock up 6% in after-hours trading.

Announcements· Dec 29

The FDA has accepted Inovio Pharmaceuticals' BLA for INO-3107, a treatment for adults with recurrent respiratory papillomatosis, with a review goal date set for October 30, 2026.
The FDA has noted that Inovio has not submitted adequate information to justify eligibility for the accelerated approval pathway for INO-3107.
Inovio Pharmaceuticals announced that the FDA has accepted its Biologic License Application for INO-3107, aimed at treating recurrent respiratory papillomatosis in adults, with a review goal date set for October 30, 2026.

Controversies· Apr 23

Inovio Pharmaceuticals' COVID-19 vaccine candidate, INO-4800, has lost DoD funding for its Phase 3 trial due to rapid vaccine deployment.
The company is planning to conduct a global Phase 3 trial for INO-4800 outside of the US, excluding federal government funding.
Inovio's stock has plummeted after the announcement, with some investors and analysts speculating about potential lawsuits related to the company's handling of vaccine development and funding.

Technical Analysis· Oct 10

$INO is expected to break through $0.60, with a potential move to $1 if it succeeds.
The stock is waiting to close a gap at $0.3750 to continue its upward trend.
The put/call ratio for $INO is extremely low and bullish, indicating a high likelihood of an upward move.

Generated by AI

Community

Of the messages about INO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	78.57%	62.57%	78.54%	79.06%
Newcomers	21.43%	37.43%	21.46%	20.94%

Regulars· Sep 29

The FDA has begun reviewing Inovio's application for the VGX-3100 in China, and experts believe it has a strong chance of approval.
The small sample size of the 3107 trial, where one patient received Avastin despite the protocol, may raise concerns with the FDA, which could impact the trial's outcome.
Inovio's management has failed to support investors, and the system has made short sellers billionaires while true shareholders suffer.

Newcomers· Aug 19

The newcomer is focused on the recent price movement of Inovio Pharmaceuticals ($INO), noting its strong performance over the last 1.5 weeks and expressing optimism about its future.
The newcomer is concerned about the potential impact of dilution on Inovio Pharmaceuticals' stock price, highlighting the company's massive wall of dilution and outstanding warrants.
The newcomer is speculating about Inovio Pharmaceuticals' future, predicting that it will "come crashing down" after a certain event (CRL) and suggesting that Moderna's strong pre-market performance may affect the bio-pharmaceutical sector.

Generated by AI

News

Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors

14h agomarketwatch.com

Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors

4d agoMarketWatch

Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors

5d agomarketwatch.com

Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors

6d agoMarketWatch

Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day

7d agoMarketWatch

Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day

12d agoMarketWatch

Also Discussed

Investors talking about INO also mention

#	Name	Attention
1	Co-Diagnostics Inc.CODX	0%+0
2	VXRT - Vaxart, Inc.	——
3	iBio, Inc.IBIO	0%0
4	Novavax Inc.NVAX	0.06%+0.01
5	Nanoviricides Inc.NNVC	0%0
6	Sorrento Therapeutics Inc.SRNE	0%0
7	Aytu BioPharma, Inc.AYTU	0%0
8	Gilead Sciences, Inc.GILD	0%-0.04
9	OPKO Health, Inc.OPK	0%0
10	AstraZeneca PLC American Depositary SharesAZN	0.02%+0.02

Inovio Pharmaceuticals Inc.

Healthcare
Biotechnology

Inovio Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines for HPV-related diseases, cancer, and infectious diseases. The company’s work centers on DNA-based immunotherapies and vaccines designed to help prevent or treat conditions such as recurrent respiratory papillomatosis, cervical dysplasia, and other virus-associated or oncology indications. Its platform combines synthetic DNA design with proprietary delivery technology to support immune-system activation across a range of therapeutic areas. Inovio’s current product pipeline reflects an emphasis on diseases linked to human papillomavirus as well as selected infectious and cancer-related programs. Based in Plymouth Meeting, Pennsylvania, Inovio Pharmaceuticals Inc. occupies a specialized position in the biotechnology market as a developer of next-generation DNA medicine technologies.

Website

Location

660 West Germantown Pike

Plymouth Meeting, PA, 19462

United States

Social

What share of all stock conversation is about INO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% 0	0% -0.01

Sep 29

Fosun Pharma has acquired exclusive rights to market VGX-3100 in China and Greater China for ~ $108M.
VGX-3100 has been successful in clinical trials, with experts praising its potential.
The company is awaiting FDA label negotiations, with some investors expecting a price increase once negotiations are confirmed.

Generated by AI

Sentiment

Of the messages about INO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	80% +13.33	68.66% -13.89	82.57% -8.7	88.54% +2.83
Bearish	20% -13.33	31.34% +13.89	17.43% +8.7	11.46% -2.83

Bullish· Sep 3

Institutional buying is evident, with huge candles forming in the stock's chart.
The FDA's acceptance of Inovio's BLA application historically leads to a high approval rate, with around 70-80% of accepted applications being approved in the first review cycle.
The stock's upward momentum is poised to continue, with the potential for a 100% increase in price over the coming weeks, given its current valuation and upcoming binary event.

Bearish· May 21

The company's warrant overhang is a significant burden, with warrant holders potentially shorting the stock, leading to a potential collapse.
The recent news about the company's product is a "nothing burger" and confirms the desperate state the company is in, with a long and uncertain timeline for final approval.
The stock's lack of movement despite significant news, including a potential cure for all types of cancer, is due to the company's management and the stock's dilution, making it unlikely to make a meaningful move.

Generated by AI

Topics

Of the messages about INO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	94.74%	76.06%	77.01%
Technical Analysis	0%	0%	9.86%	17.13%
Controversies	0%	5.26%	9.86%	3.07%
Macro	0%	0%	4.23%	0.31%
Earnings	0%	0%	0%	0.69%
Analysts	0%	0%	0%	1.79%

Earnings· Mar 1

Inovio Pharmaceuticals reported a loss of $0.50 per share, missing the consensus estimate of a loss of $0.33 per share.
The company's revenue of $1.77 million beat the consensus estimate of $1.46 million.
Inovio's net loss widened significantly in the fourth quarter, with a net loss of $106.9 million, a 340% increase from the prior-year period.

Analysts· Feb 12

Oppenheimer analyst Hartaj Singh initiated coverage on Inovio Pharmaceuticals with an Outperform rating and a $35 price target, citing the company's differentiated COVID-19 vaccine and overall DNA platform.
Singh believes Inovio's COVID-19 vaccine has a better safety and tolerability profile, which could generate higher uptake in a low-risk population, and that the company's overall DNA platform "should not be overlooked".
Inovio Pharmaceuticals shares are trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and announced a $35 price target, with the stock up 6% in after-hours trading.

Announcements· Dec 29

The FDA has accepted Inovio Pharmaceuticals' BLA for INO-3107, a treatment for adults with recurrent respiratory papillomatosis, with a review goal date set for October 30, 2026.
The FDA has noted that Inovio has not submitted adequate information to justify eligibility for the accelerated approval pathway for INO-3107.
Inovio Pharmaceuticals announced that the FDA has accepted its Biologic License Application for INO-3107, aimed at treating recurrent respiratory papillomatosis in adults, with a review goal date set for October 30, 2026.

Controversies· Apr 23

Inovio Pharmaceuticals' COVID-19 vaccine candidate, INO-4800, has lost DoD funding for its Phase 3 trial due to rapid vaccine deployment.
The company is planning to conduct a global Phase 3 trial for INO-4800 outside of the US, excluding federal government funding.
Inovio's stock has plummeted after the announcement, with some investors and analysts speculating about potential lawsuits related to the company's handling of vaccine development and funding.

Technical Analysis· Oct 10

$INO is expected to break through $0.60, with a potential move to $1 if it succeeds.
The stock is waiting to close a gap at $0.3750 to continue its upward trend.
The put/call ratio for $INO is extremely low and bullish, indicating a high likelihood of an upward move.

Generated by AI

Community

Of the messages about INO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	78.57%	62.57%	78.54%	79.06%
Newcomers	21.43%	37.43%	21.46%	20.94%

Regulars· Sep 29

The FDA has begun reviewing Inovio's application for the VGX-3100 in China, and experts believe it has a strong chance of approval.
The small sample size of the 3107 trial, where one patient received Avastin despite the protocol, may raise concerns with the FDA, which could impact the trial's outcome.
Inovio's management has failed to support investors, and the system has made short sellers billionaires while true shareholders suffer.

Newcomers· Aug 19

The newcomer is focused on the recent price movement of Inovio Pharmaceuticals ($INO), noting its strong performance over the last 1.5 weeks and expressing optimism about its future.
The newcomer is concerned about the potential impact of dilution on Inovio Pharmaceuticals' stock price, highlighting the company's massive wall of dilution and outstanding warrants.
The newcomer is speculating about Inovio Pharmaceuticals' future, predicting that it will "come crashing down" after a certain event (CRL) and suggesting that Moderna's strong pre-market performance may affect the bio-pharmaceutical sector.

Generated by AI

Inovio Pharmaceuticals

Social

Sep 29

Bullish· Sep 3

Bearish· May 21

Earnings· Mar 1

Analysts· Feb 12

Announcements· Dec 29

Controversies· Apr 23

Technical Analysis· Oct 10

Regulars· Sep 29

Newcomers· Aug 19

Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors

Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors

Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors

Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors

Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day

Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day

Also Discussed

Inovio Pharmaceuticals Inc.

Company Information

Location

Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors

Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors

Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors

Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors

Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day

Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day

Also Discussed

Social

Sep 29

Bullish· Sep 3

Bearish· May 21

Earnings· Mar 1

Analysts· Feb 12

Announcements· Dec 29

Controversies· Apr 23

Technical Analysis· Oct 10

Regulars· Sep 29

Newcomers· Aug 19